Revenio Group Oyj
Revenio Group Oyj is a Finnish public health tech company that designs, manufactures, and sells ophthalmic diagnostic devices and software under the iCare and Visionix brands, serving ophthalmologists, optometrists, and optical retailers in over 100 countries.
- Company typePublic
- Founded2009
- HeadquartersVantaa, Finland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Revenio Group Oyj does
Revenio Group Oyj is a Finnish public health technology company (Nasdaq Helsinki: REG1V) headquartered in Vantaa, focused on ophthalmic diagnostic devices and software. Its product portfolio spans intraocular pressure tonometers (iCare IC100, IC200, ST500, HOME2), fundus imaging systems (EIDON AF, DRSplus), the COMPASS combined perimeter and fundus imager, and veterinary tonometry (TONOVET Pro and Plus). Software offerings include the iCare ILLUME AI screening solution for diabetic retinopathy, AMD and glaucoma (powered by RetCAD from the August 2024 Thirona Retina acquisition), iCare CLINIC cloud-based data management, the PATIENT2 patient app for home IOP monitoring, and the Oculo clinical communication and telehealth platform. The May 2026 acquisition of Visionix International (LT International SAS) for EUR 290 million enterprise value added OCT systems, refraction devices, multimodal diagnostic platforms, and lens finishing solutions to the portfolio, taking combined revenue above EUR 250 million and the headcount to over 800.
The company operates a multi-brand go-to-market under the iCare and Visionix brands, distributing products to ophthalmologists, optometrists, and optical retailers in over 100 countries via a hybrid of distributors and direct sales subsidiaries (Icare USA Inc. since 2012; China iCare Medical Technology Co. Ltd. since October 2022). Revenue is generated through four streams: hardware sales of diagnostic devices (the largest contribution), recurring revenue from single-use iCare sensors, software subscriptions (iCare CLINIC, Oculo, ILLUME), and service and support. FY2025 standalone net sales were EUR 109.7 million with an EBIT margin of 23.2%, and the company is regulated under multiple medical device frameworks including EU MDR, ISO 13485, ISO 27001, and MDSAP, providing market access across the EU, US, Canada, Brazil, Japan, and Australia. Major shareholder William Demant Invest (associated with Danish hearing care group Demant) holds 22.4% post-deal; Visionix CEO Marc Abitbol and Charles Vilgrain of Caravelle Capital joined the board as part of the acquisition consideration.
Revenio Group Oyj firmographics
Firmographics- Name
- Revenio Group Oyj
- Legal name
- Revenio Group Oyj
- Website
- https://reveniogroup.fi
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Revenio Group Oyj is a Finnish public health tech company that designs, manufactures, and sells ophthalmic diagnostic devices and software under the iCare and Visionix brands, serving ophthalmologists, optometrists, and optical retailers in over 100 countries.
- Ownership category
- akta.pro rank
Revenio Group Oyj industry classification
Industry- Product category
- Ophthalmic Diagnostic Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD)
- akta.pro secondary industry
- Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Revenio Group Oyj is headquartered
LocationHeadquarters
- HQ city
- Vantaa
- HQ country
- Finland
- HQ region
- Europe
Offices2 records
Markets served
Revenio Group Oyj business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales (iCare and Visionix Brands): Sale of ophthalmic diagnostic equipment including tonometers, fundus imaging devices, OCT solutions, perimeters, refraction devices, and accessories. Revenue from device hardware sales through distributors and direct sales network.
- Sensor Sales (Recurring Revenue): Sale of single-use sensors for iCare tonometers. Creates recurring revenue stream from consumables used with diagnostic devices.
- Software Solutions: Clinical software solutions including iCare ILLUME, iCare CLINIC, Oculo platform, and RetCAD AI diagnostics. Software licenses and subscriptions supporting device ecosystem.
- Service and Support: Maintenance, calibration, and support services for diagnostic equipment.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Revenio Group Oyj product offering
Product offeringCore offering
Revenio designs, manufactures and sells ophthalmic diagnostic devices and supporting clinical software under the iCare and Visionix brands. Its portfolio includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2, TONOVET Plus/Pro), TrueColor Confocal fundus imaging systems (EIDON AF, DRSplus), the COMPASS perimeter, AI-powered screening (iCare ILLUME, RetCAD), the Oculo cloud-based eye care software platform, and Visionix OCT, refraction, multimodal diagnostic, and finishing solutions. Products are sold to ophthalmologists, optometrists, optical retailers, and veterinary clinics across more than 100 countries through distributors and the company's own sales subsidiaries.
Product overview
Revenio Group Oyj offers a comprehensive portfolio of ophthalmic diagnostic solutions under the iCare and Visionix brands. The iCare brand includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2), veterinary tonometry (TONOVET Pro, TONOVET Plus), fundus imaging devices (EIDON AF, DRSplus), perimetry systems (COMPASS), and cloud-based software solutions (ILLUME with AI screening, CLINIC, PATIENT2 app). Visionix products include Optical Coherence Tomography (OCT), refraction systems, multimodal diagnostic platforms, and finishing solutions, acquired in 2026. The combined portfolio serves optometry, optical retail, and ophthalmology with devices, imaging solutions, refraction technologies, software, and workflow solutions across over 100 countries. Key AI capability is embedded in iCare ILLUME for automated screening of diabetic retinopathy, AMD, and glaucoma.
Differentiator
Problem solved
Functional benefit
Products and services
- iCare IC100 Handheld rebound tonometer for measuring intraocular pressure (IOP) in seated or standing patients, used for routine eye pressure measurements and glaucoma screening by eye care professionals.
- iCare IC200 Multi-purpose flagship rebound tonometer for clinical, surgical, and emergency use with 200-degree freedom of movement, measuring IOP in any patient position.
- iCare ST500 Slit-lamp-mounted tonometer incorporating iCare's rebound technology for efficient and patient-friendly eye pressure measurement, streamlining clinical workflow.
- iCare HOME2 Home-use eye pressure monitor enabling patients to measure IOP in daily life settings, with data transmitted securely to healthcare providers via the companion PATIENT2 application.
- iCare TONOVET Plus Veterinary rebound tonometer for measuring eye pressure in animal patients, used by veterinarians and animal eye specialists.
- iCare TONOVET Pro Flagship veterinary tonometer with 200-degree positioning freedom, designed for professionals requiring advanced features in accuracy and usability, including surgery and emergency use.
- iCare EIDON AF TrueColor Confocal fundus imaging system with widefield imaging capabilities and fully automated operation, available in three models covering various imaging methods.
- iCare DRSplus Non-mydriatic fundus camera capable of capturing high-quality images from small pupils (2-2.5mm) and through cataracts or media opacities using confocal technology.
- iCare COMPASS Perimeter combining visual field examination with high-resolution confocal fundus imaging in a single device, achieving better reproducibility than existing standards.
- iCare ILLUME AI-powered screening solution combining artificial intelligence with TrueColor Confocal fundus imaging for automated detection of diabetic retinopathy, age-related macular degeneration, and glaucoma, with a fully automated workflow and ILLUME Connect for referral sharing.
- Oculo Australian cloud-based eye care software platform combining clinical communication, telehealth, patient remote monitoring, and data analytics, connecting care teams and electronic medical records with imaging systems.
- Visionix OCT Solutions Optical Coherence Tomography equipment providing high-resolution cross-sectional imaging of retinal structures, representing a growing segment newly acquired through the 2026 Visionix merger.
- Visionix Refraction Systems Refraction devices and systems for measuring refractive errors of the eye, part of Visionix's complementary product portfolio acquired in 2026 for the optometry and optical retail market.
- Visionix Multimodal Diagnostic Platforms Multimodal diagnostic platforms combining multiple imaging modalities for comprehensive eye examination, part of Visionix's portfolio acquired in 2026.
- Visionix Finishing Solutions Lens finishing solutions for eyewear prescription fulfillment, part of Visionix's comprehensive product portfolio acquired in 2026.
Quantifiable outcome
- Improves diagnostic efficiency and quality of care throughout patient journey
- +2 more outcomes
Companies that use Revenio Group Oyj
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Revenio Group Oyj technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
Revenio Group Oyj partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- iCare, epitop, bon OpticminorStrategic partnership for screening and reform of optometric care models. The partnership aims to advance eye disease screening and improve optometric treatment approaches.
Scale indicators9 records
Recent moves12 records
Expansion highlights8 records
Revenio Group Oyj competitors and assessment
Company assessmentDirect peers
- Haag-Streit Group: Swiss ophthalmic device manufacturer with strength in perimetry, slit lamps, tonometry, and imaging. Overlaps with Revenio's COMPASS perimeter and iCare imaging products in the same clinical and academic eye care channels.
- Topcon Corporation: Major Japanese manufacturer of OCT devices, fundus cameras, and ophthalmic diagnostic equipment, with a strong direct-sales network and optometry channel presence. Closely comparable to Revenio/Visionix in OCT and screening product categories serving optometrists and ophthalmologists globally.
- Centervue (now part of Revenio): Italian fundus camera and perimeter manufacturer acquired by Revenio in 2019; relevant as a directly comparable niche diagnostic imaging player now subsumed into the combined entity.
- Heidelberg Engineering GmbH: German manufacturer of diagnostic imaging devices including OCT, fundus imaging, and perimetry systems. Directly competes with Revenio's imaging and perimetry products, with strong specialist/ophthalmology presence in Europe and global reach.
- Nidek Co., Ltd. Japanese maker of ophthalmic diagnostic devices including OCT, fundus cameras, tonometers, and refractive equipment. Directly competes with Revenio's iCare tonometers and Visionix refraction devices across global optical retail and ophthalmology channels.
- Optos plc: Manufacturer of ultra-widefield retinal imaging devices (optomap) competing directly with iCare EIDON AF and DRSplus fundus cameras in optometry, optical retail, and screening settings worldwide.
Emerging players
- Eyenuk, Inc. US-based AI eye-screening company (EyeArt) providing autonomous diabetic retinopathy detection. Directly competes with RetCAD/iCare ILLUME AI screening workflows in optometry and primary care channels.
- Pulsenmore Ltd. Israeli developer of handheld prenatal ultrasound; comparable as a healthcare diagnostic device company in which board member Anat Loewenstein has involvement, illustrating adjacent diagnostic device business models relevant to Revenio's growth pattern.
Broad incumbents
- Alcon Inc. Global ophthalmic medtech leader with surgical, vision care, and growing diagnostic/imaging offerings. Competes with Revenio's broader ophthalmic portfolio across channels and has substantially greater scale and R&D budget.
- Carl Zeiss Meditec AG: One of the largest ophthalmic diagnostic and surgical device manufacturers globally, with extensive OCT, fundus imaging, and refractive product lines. Directly overlaps with Revenio's iCare and Visionix portfolios and competes for the same optometry and ophthalmology customers worldwide.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Revenio Group Oyj social profiles
Digital presenceRevenio Group Oyj compliance and trust
Trust signalCompliance4 records
Revenio Group Oyj financial estimates
Financial estimateRevenue estimate
Valuation estimate
Revenio Group Oyj leadership team
Management profileNumber of profiles
Profiles6 records
Revenio Group Oyj subsidiaries and ownership
Company hierarchySubsidiaries7 records
Revenio Group Oyj funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Revenio Group Oyj M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Revenio Group Oyj
What does Revenio Group Oyj do?
Revenio designs, manufactures and sells ophthalmic diagnostic devices and supporting clinical software under the iCare and Visionix brands. Its portfolio includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2, TONOVET Plus/Pro), TrueColor Confocal fundus imaging systems (EIDON AF, DRSplus), the COMPASS perimeter, AI-powered screening (iCare ILLUME, RetCAD), the Oculo cloud-based eye care software platform, and Visionix OCT, refraction, multimodal diagnostic, and finishing solutions. Products are sold to ophthalmologists, optometrists, optical retailers, and veterinary clinics across more than 100 countries through distributors and the company's own sales subsidiaries.
Is Revenio Group Oyj a public or private company?
Revenio Group Oyj is a public company. It is classified as public and is currently operating.
When was Revenio Group Oyj founded?
Revenio Group Oyj was founded in 2009. It employs 101 to 250 people.
Where is Revenio Group Oyj based?
Revenio Group Oyj is headquartered in Vantaa, Finland, in the Europe region.
How does Revenio Group Oyj make money?
Four revenue lines are on record. Medical Device Sales (iCare and Visionix Brands) is the primary driver. The others are sensor Sales (Recurring Revenue), software Solutions and service and Support.
Who are Revenio Group Oyj's main competitors?
Direct peers on record are Haag-Streit Group, Topcon Corporation, Centervue (now part of Revenio), Heidelberg Engineering GmbH, Nidek Co., Ltd. and Optos plc. Emerging players are Eyenuk, Inc. and Pulsenmore Ltd.. Broad incumbents are Alcon Inc. and Carl Zeiss Meditec AG.
Does Revenio Group Oyj have an API?
No public API is recorded for Revenio Group Oyj.
What industry is Revenio Group Oyj in?
Revenio Group Oyj's product category is Ophthalmic Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAD, Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment), with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 339115 and its SIC code is 3851.